Investor Presentation
|
|
- Rafe Lane
- 5 years ago
- Views:
Transcription
1 (Nasdaq: INSY) Investor Presentation Cantor Global Healthcare Conference October 2, 2018
2 Safe-Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements are based on management s current expectations and assumptions as of the date of this presentation, and actual results may differ materially from those in these forward-looking statements as a result of various factors, including many which are beyond INSYS control. Such factors include, but are not limited to, risks regarding: INSYS ability to commercialize products successfully; INSYS ability to successfully manage its commercial relationships and sales infrastructure; INSYS ability to obtain anticipated governmental or regulatory approvals; INSYS failure to finalize documents with the DOJ and OIG or to comply with post-approval regulatory and governmental requirements; the actual sales potential and opportunity of identified markets; INSYS ability to manage and resolve, under acceptable terms and conditions, its ongoing legal proceedings and litigation, including various governmental investigations; and INSYS ability to realize the expectations of its pipeline and product candidate plans and timelines. For a further description of these and other risks facing INSYS, please see the risk factors described in the company s filings with the United States Securities and Exchange Commission, including those factors discussed under the caption Risk Factors in those filings. All the information included herein is dated information concerning the company. The company disclaims and does not undertake any obligation to update or revise any forward-looking statements or historical information contained herein. 2
3 Investment Thesis NASDAQ Key Facts INSY Emerging leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology Founded 2002 Headquarters Chandler, AZ TTM Revenue * $110M Cash on Hand * $124M Transformation from opioid focus to Cannabinoids/Sprays Driven by new management, governance, employee base, vision and culture Current commercial products provide platform to support transformation R&D Investment ~$250M since 14 Deep, well-differentiated pipeline across cannabinoids and spray platforms Potential for at least five NDAs through 2021 Two FDA-approved products available in U.S. SUBSYS (fentanyl sublingual spray) launched in 2012 SYNDROS (dronabinol) oral solution launched in 2017 *as of 6/30/18 State of the art manufacturing facility approved by DEA and FDA U.S. based synthetic cannabinoid manufacturing facility that can produce at scale Long-term competitive advantage: proprietary synthetic CBD process (99%+ pure) 3
4 Two Innovative Drug Development Platforms Oral Solution Inhalation 1) Pharmaceutical Cannabinoids SYNDROS Pharmaceutical THC Oral Solution Product Oral Solution Delivery (launched Aug 17) Inhalation Delivery (in development) Cannabidiol (CBD) Product Pipeline Oral Solution Delivery (in development) Disease States Under Investigation Childhood Absence Epilepsy Infantile Spasms Prader-Willi-Syndrome Anorexia in Cancer Sublingual 2) Spray Technology Nasal Drug delivery via fine mist: Under the tongue (sublingual) SUBSYS In the nasal cavity (intranasal) Targeting patient populations and disease states where spray product characteristics add value Clinically beneficial faster speed of onset Ease of use / application Disease States Under Investigation Anaphylaxis Opioid Overdose Opioid Dependence Pain 4
5 Two FDA-Approved Commercial Products Indicated for: Management of breakthrough cancer pain in opioid-tolerant adult cancer patients Branded market leader in TIRF class (TIRF = Transmucosal Immediate Release Fentanyl) Script share 1 ~28% Unit share 1 ~33% Meaningfully differentiated: Better bioavailability than Actiq Rapid onset of action Simple one-step administration process Widest dose range Proprietary sublingual spray formulation Recently started to expand commercial presence internationally Lunatus in Middle East Other regions under consideration Indicated for: Anorexia associated with weight loss in patients with AIDS Chemotherapy-induced nausea and vomiting (CINV) in patients with cancer whose response to conventional antiemetics is inadequate Potential addressable population: ~800K in CINV ~90K in AIDS anorexia Conservative launch August 2017 with slow uptake comparable with other CII products Life-cycle management: Novel inhalation device Proof-of-concept study Q Exploring label expansion (anorexia in cancer) 1 Exit share as of August 2018 (source: IQVIA) 5
6 Strategic Roadmap & Key Priorities Our Vision Improve the quality of patient care by building a specialty pharmaceutical company focused on cannabinoids and novel drug delivery systems that address unmet patient needs. Our Priorities Resolve Government Investigations & Rebuild Reputation Building new culture of compliance and ethics Reached agreement in principle with DOJ Strengthen the Foundation & Enhance Execution Recruiting & retaining people of character & experience Augmenting capabilities & optimizing processes Advance and Develop Diverse Pipeline to Drive Future Growth Shifting from opioids to cannabinoids Three major programs underway in CBD Exploring collaborative research partnerships Stabilize and Grow Marketed Portfolio Sales Force talent upgrade & realignment Expanding managed care contracts & patient services Exploring international expansion Supported by: Strong Culture of Compliance 6
7 Legal Landscape 1 1) Department of Justice Resolve Government Investigations & Rebuild Reputation Settlement Agreement in Principle as of August 8, 2018 $150 million payable over five years Management estimate of $0 to $75 million in potential contingencybased payments When documentation finalized, resolves both criminal and civil charges 2) Individual State Suits Settled with 4 states Received subpoenas from 15+ states Pending suits from 8 states 7
8 New Leadership Across the Organization Saeed Motahari President & CEO 20-year veteran in the life sciences industry Hoffmann-La Roche Bristol-Myers Squibb Abbott Laboratories & AbbVie Purdue Pharma Executive Leadership Andy Long Chief Financial Officer 30+ years in financial leadership positions across bio pharma, life sciences, and industrial sectors Patheon Thermo Fisher Abbott Laboratories Executive Leadership Dr. Ahmed Elkashef, M.D. Vice President of Clinical Development 30+ years of clinical practice and research experience National Institute on Drug Abuse (N.I.D.A.) U.A.E. s National Rehabilitation Center N.I.H. s National Institute on Mental Health (N.I.M.H.) Clinical Development Dr. Dean Mariano, D.O. Senior Director of Clinical Development & Medical Affairs 15+ years of pain management practice experience President of CT Pain Society Chairman of the CT State Medical Society s Task Force on Opioids Clinical Development 2 Strengthen the Foundation & Enhance Execution ~40% of current employees have less tenure than CEO Brian Jennings VP, Sales 25+ years of industry experience Purdue Pharma Publicis Healthcare Group Sanofi Roche U.S. (Genentech) Unimed Carol Summersgill VP Human Resources 20+ years of HR leadership Libbey Inc. Philosophy, Inc. Therma-Tru Doors, Inc. Whirlpool Corp. Ariyapadi Krishnaraj VP, Commercial 30+ years in industry and consulting experience Iroko Pharmaceuticals Novartis GlaxoSmithKline Consultant: Endo & Takeda Scott Warlick General Manager & Director of Manufacturing 15+ years in site management, operations, maintenance, process engineering/optimization Mylan Mallinckrodt ~50% of current sales reps joined INSYS in 2017 and 2018 More than two-thirds of company s Board is new since April 2017 Executive Leadership Executive Leadership Executive Leadership Manufacturing 8
9 Unique Manufacturing Capabilities Facilities (DEA & FDA-approved): Invested ~$14M since 2016 in manufacturing capabilities Oakmont plant 83,000 sq. ft. for cannabinoid API * and finished drug product Paloma plant 8,000 sq. ft. for cannabinoid API * only Process Technology: 2 Strengthen the Foundation & Enhance Execution Developed and IP-owned by INSYS Improving capacity, yield and purity of CBD synthesis Easy to expand for additional capacity People: Strong leadership team with extensive experience in API production leading ~50 fully trained employees Systems: cgmp compliance successfully passed FDA inspection multiple times Meeting all requirements from DEA, EPA, OSHA and other government regulations * API = Active Pharmaceutical Ingredient 9
10 SPRAYS CANNABINOIDS Deep Pipeline to Drive Long-Term Growth Drug Candidate Disease State Non-Clinical Phase 1 Phase 2 Phase 3 Submit Approval (i) Childhood Absence Epilepsy Ph 2 Enrolling (n=30) Cannabidiol (CBD) Oral Solution (ii) Infantile Spasms Ph 3 Initiated (n=190) Orphan Drug Designation Granted Aug 2015 (iii) Prader-Willi Syndrome Ph 2 Enrolling (n=66) Fast Track Designation Granted Dec 2017 Dronabinol Inhalation Anorexia in Cancer In Dev PK Study Completed Sept 2018 Naloxone* Nasal Spray Opioid Overdose PK Completed NDA Filing 1Q2019** Epinephrine* Nasal Spray Anaphylaxis PK Completed Fast Track Designation Granted Aug 2018 Buprenorphine/Naloxone Sublingual Spray Opioid Dependence In Dev Buprenorphine Sublingual Spray Moderate-to-Severe Acute Pain NDA Filed CRL Rec d July 2018 *Pursuing 505(b)2 bioequivalence approach for potential approval **FDA requires additional juvenile nonclinical toxicity studies as part of the pediatric plan. 10
11 Pipeline Priority and Valuation Pipeline Project Assessment 1 Market Potential Ranking High 1) CBD Investment 2 Dronabinol Inhalation CBD Epinephrine 2) Epinephrine 3) Dronabinol Inhalation 4) Buprenorphine/Naloxone 5) Naloxone Medium to high market opportunity Low to medium market opportunity Low Bup/ Naloxone Naloxone Bup Early Project Status 3 Late 1 Pipeline assets have been prioritized after an assessment of investment, project progress and market attractiveness (represented by bubble size). 2 Investment refers to projected remainder development costs. 3 Project status as of
12 Over 16 years Cannabinoid Experience Over 16 years of experience working with Cannabinoids 2 Cannabinoid (THC capsule and oral solution) products approved by FDA CBD oral solution currently in development Three CBD clinical trials currently underway Childhood Absence Epilepsy (CAE) Infantile Spasms (IS) Prader-Willi Syndrome Completed 5 studies in Cannabidiol (CBD) in the last five years Over 150 subjects dosed with INSYS oral solution CBD 25 patients in the Expanded Access Program have been on CBD for over 3 years Generally well-tolerated adverse event profile, commonly reported AEs included diarrhea and somnolence 12
13 Completed CBD Trial INS Title: A Phase 1/2 study to assess the pharmacokinetics and safety of multiple doses of pharmaceutical Cannabidiol Oral Solution in pediatric subjects with treatment-resistant seizure disorders Number of patients: 61 Number of sites: 10 Objectives: To characterize the PK of Cannabidiol Oral Solution in pediatric subjects with treatment-resistant seizures To assess the safety of Cannabidiol Oral Solution in pediatric subjects with treatment-resistant seizures To assess any improvement in qualitative assessments of subject status over the duration of the study Data Presented at American Epilepsy Society (AES) Meeting 2017 Title: Pharmacokinetics and Tolerability of Multiple Doses of Pharmaceutical-Grade Synthetic Cannabidiol Oral Solution in Pediatric Patients With Treatment-Resistant Seizure Disorders 13
14 INS : High-Level Result Summary Three doses of 10mg/kg/day, 20mg/kg/day and 40mg/kg/day were studied in patients 1-17yrs old with treatment resistant seizure disorders (61 subjects enrolled) Steady state level of CBD observed by Day 4 after repeated dosing Dose proportionality established between doses Generally well tolerated adverse event profile, commonly reported AEs included diarrhea and somnolence 52 of 61 patients in the 029 PK enrolled in the 030 long-term safety study Results of long-term study demonstrate that all Cannabidiol Oral Solution doses were generally well-tolerated even at doses as high as 40 mg/kg/day Of the 52 patients that rolled into the 030 Long Term Safety Study, 45 completed the 48-week study and 25 currently remain on CBD in the Expanded Access Program American Epilepsy Society (AES) Meeting Q Abstract presentation : Long-Term Safety of Pharmaceutical Cannabidiol Oral Solution as Adjunctive Treatment for Pediatric Patients With Treatment-Resistant Epilepsy 14
15 Ongoing CBD Clinical Trials Infantile Spasms Child Absence Epilepsy Prader-Willi Syndrome Orphan drug status granted July 2015 Onset age: 1 24 months EEG shows hypsarrhythmia Prevalence: 98,062 children Usually staring spells lasting seconds 2% 8% of people with epilepsy Two-thirds with CAE respond to treatment Prevalence: 9,400 37,600 children Fast Track Review Granted December 2017 Mutation in 15q11 13 (paternal) 25% mortality by age 18 Insatiable appetite Prevalence: 1 per 10,000 30,000 Phase 3 Actively Enrolling % of patients considered complete responders, defined as complete resolution of spasms and hypsarrhythmia confirmed by 24-hr video-eeg from Day 14 to Day 15. Phase 2 Actively Enrolling At Week 4 vs. baseline: % change in absence sz counts % change in time to absence sz during hyperventilation testing % patients sz free based on sz diary Investigator CGI-I* at Week 4 Phase 2 Actively Enrolling Change in total score of Hyperphagia Questionnaire for Clinical Trials (HQ-CT) through study completion or early withdrawal. * CGI-I = Clinical Global Impression Improvement Scale Source: (1) Cowan and Hudson 1991 (2) Foundation for PW Research (3) Trevathan, Murphy, Yeargin-Allsopp 1999 (4) Jallon and Latour 2005 (5) RareDiseases.org 15
16 CBD Clinical Trials - Phase 3 Infantile Spasms Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of Cannabidiol Oral Solution as Adjunctive Therapy with Vigabatrin as Initial Therapy in Patients with Infantile Spasms Status: Actively enrolling Sites: approximately 40 sites in US and ex-us Objectives: Primary: To evaluate the efficacy of Cannabidiol Oral Solution as adjunctive therapy with vigabatrin as initial therapy in treating patients with Infantile Spasms Secondary: To evaluate the continued efficacy of Cannabidiol Oral Solution after the 14-day treatment with vigabatrin or vigabatrin plus Cannabidiol Oral Solution is complete To evaluate the safety and tolerability of Cannabidiol Oral Solution as adjunctive therapy with vigabatrin as initial therapy in treating patients with Infantile Spasms Results from Phase 2 study, CBD monotherapy for double refractory Infantile Spasms (1 out 7 enrolled had a complete response) Shifted the development program to investigate CBD as adjunctive therapy for initial therapy in Infantile Spasms Data Presented at American Epilepsy Society Meeting 2017 Title: A Phase-2 Study of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms 16
17 Collaborative CBD Trials Under Consideration Autism Early Psychosis Anorexia Nervosa Childhood Schizophrenia/ Early Psychosis Collaborating with University of California San Diego School of Medicine s Center for Medicinal Cannabis Research Orphan Drug Designation Possible collaboration with NIMH Addiction Possible collaboration with NIDA and NIAAA Post-Traumatic Stress Disorder Possible collaboration with DOD and VA 17
18 Epinephrine Nasal Spray: Fast Tracked Received Fast Track Designation from FDA in August 2018 Prior pharmacokinetic study of 60 people with seasonal allergies demonstrated rapid drug absorption Showed bioavailability of the company s novel, proprietary formulation of epinephrine delivered intranasally was similar to that of intramuscular injection with EpiPen (0.3 mg) Anaphylaxis is acute, life-threatening systemic allergic reaction U.S. incidence: 200,000+ cases per year 1 Worldwide prevalence: lifetime risk globally per person of 0.5 2% 2 ~$1.7 billion U.S. market in 2017 with ~25% CAGR ( ) 3 Epinephrine is most important medicine to give during life-threatening anaphylaxis 4 Current epinephrine products are all invasive Supply shortage of auto-injectors / injectables in U.S. Meaningful clinical opportunity for potential nasal spray American Academy of Allergy, Asthma & Immunology (AAAI) Annual Meeting 2019 Abstract submitted to present PK Study Data (pending acceptance) 1 Mayo Clinic, 2 World Allergy Organization, 3 IQVIA, 4 Symphony Health Solutions 18
19 Naloxone Global Market Value (US M$) Naloxone: NDA Preparation Human Factors Study completed Ongoing nonclinical studies recently requested by FDA prior to NDA submission NDA submission target date: Q1 2019* Strategy for filing 1. Fast Absorption 2. Higher Exposure (AUC) than all Narcan/Naloxone preparations 3. Longer duration (up to 2 hours) formulation to combat the rising epidemic of synthetic opioids overdose *FDA requires additional pediatric nonclinical toxicity studies as part of the pediatric plan. $1,000 $900 $800 $700 $600 $500 $400 $300 $200 $100 Global Naloxone Market Value Estimates (USD $M) $0 $ (A) $310 $372 $ (A) 2018 (E) 2019 (E) $ (E) $ (E) $ (E) $ (E) $ (E) Source: Coherent Market Insights (Global Industry Insights: Naloxone Market) American Society of Addiction Medicine (ASAM) 2019 College on Problems of Drug Dependence (CPDD) 2019 Abstracts in development to present Naloxone PK study data $ (E) $885 Note: US represents ~75% in 2018 with increasing shares from EU (upto ~33% projected) in forward years 2026 (E) North America $169 $224 $279 $319 $350 $377 $403 $430 $459 $491 $525 19
20 Key R&D Projects and Milestones Drug Candidate Targeted Indication Delivery Method Recent Milestones Upcoming Milestone Naloxone Opioid Overdose Nasal Spray End of Phase 2 FDA meeting (Feb 2018) Completed PK studies Nonclinical studies to be completed in 2018 NDA filing Q1 2019* Epinephrine Anaphylaxis Nasal Spray Childhood Absence Epilepsy Proof-of-concept study enrollment completed End of Phase 2 FDA meeting (Aug 2018) Enrolling Phase 2 study NDA filing 2H 2019 Data read Q Cannabidiol (CBD) Infantile Spasms Oral Solution Enrolling Phase 3 study Data read Q Prader-Willi Syndrome Initiated and recruiting proof-of-concept study Received Fast Track designation (Dec 2017) Data read Q Dronabinol (THC) Anorexia in Cancer Inhalation Device Proof-of-concept PK study (healthy subjects) completed (Sept 2018) Advisory Board 1H 2019 * FDA requires additional juvenile nonclinical toxicity studies as part of the pediatric plan. 20
21 Projected NDA Timelines Naloxone Opioid Overdose CBD Infantile Spasms Epinephrine Anaphylaxis CBD Childhood Absence Epilepsy Dronabinol Anorexia in Cancer CBD Prader-Willi Syndrome Potential for 6 NDA s over the next 3 Years 21
22 Monthly Prescriptions Commercial Strategies Overview 4,500 4,000 3,500 3,000 2,500 2,000 1,500 1, SUBSYS and TIRF Market TRxs as of August 2018 Executing SUBSYS Stabilization Initiatives Positive signs from managed care wins Increasing awareness of breakthrough cancer pain associated with bone metastasis Exploring collaborative licensing opportunities internationally SYNDROS Brand Awareness Programs Continued Q net revenue of $1 million (56% sequential Stabilize and Grow Marketed Portfolio 4 improvement) All other TIRF SUBSYS Continuing HCP education programs Pursuing additional managed care wins Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Mar-18 Apr-18 May-18 Jun-18 Jul-18 Aug-18 SUBSYS TIRF Total 3,162 3,181 2,959 2,864 2,686 2,374 2,512 2,173 2,220 2,113 2,105 2,113 Market Share 30% 31% 30% 29% 27% 28% 27% 29% 28% 30% 28% 28% Source: IQVIA 22
23 Financial Snapshot $124M in cash at end of Q No debt Gross margins ~90% Optimizing operating expenses while fully funding R&D * Excludes settlements Rightsized commercial organization Leveraging supplier base Tight headcount controls $50 $40 $30 $20 $10 $0 $45 $40 $35 $30 $25 $20 $15 $10 $5 $0 Revenue (millions) Q2'17 Q3'17 Q4'17 Q1'18 Q2'18 Operating Expenses* (millions) Q2'17 Q3'17 Q4'17 Q1'18 Q2'18 Sales & Marketing R&D G&A Legal $3 -$2 -$7 -$12 -$17 -$22 -$27 $250 $200 $150 $100 $50 $0 Adjusted EBITDA (millions) Q2'17 Q3'17 Q4'17 Q1'18 Q2'18 Total Cash, Short-Term, Long-Term Investments (millions) Q2'17 Q3'17 Q4'17 Q1'18 Q2'18 23
24 Investment Thesis Emerging leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology Transformation from opioid focus to Cannabinoids/Sprays Driven by new management, governance, employee base, vision and culture Current commercial products provide platform to support transformation Deep, well-differentiated pipeline across cannabinoids and spray platforms Potential for at least five NDAs through 2021 State of the art manufacturing facility approved by DEA and FDA U.S. based synthetic cannabinoid manufacturing facility that can produce at scale Long-term competitive advantage: proprietary synthetic CBD process (99%+ pure) 24
25 (Nasdaq: INSY) Contact Information Jackie Marcus or Chris Hodges Alpha IR Group Phone:
Investor Presentation
(Nasdaq: INSY) Investor Presentation Janney Healthcare Conference September 18, 2018 Safe-Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking
More informationQ3 18 Earnings Supplemental Slides
(Nasdaq: INSY) Q3 18 Earnings Supplemental Slides November 5, 2018 Safe-Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements
More informationN a s d a q : I N S Y
N a s d a q : I N S Y 0 Safe Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements are based on management's current expectations
More informationGW Pharmaceuticals plc. Investor Presentation August 2014
GW Pharmaceuticals plc Investor Presentation August 2014 Forward Looking Statements and Disclaimer This presentation contains forward-looking statements. Some of the matters discussed concerning our operations
More informationJ.P. Morgan Healthcare Conference
J.P. Morgan Healthcare Conference Shire plc January 10, 2012 Angus Russell Chief Executive Officer Our purpose We enable people with life-altering conditions to lead better lives. THE SAFE HARBOR STATEMENT
More informationAXIM Biotechnologies Reports Year End 2017 Results
March 19, 2018 AXIM Biotechnologies Reports Year End 2017 Results NEW YORK, March 19, 2018 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research
More information27 th Annual J.P. Morgan Healthcare Conference. January 13, 2009
27 th Annual J.P. Morgan Healthcare Conference January 13, 2009 1 Forward Looking Statements This presentation and any subsequent Q&A may contain forward-looking statements, including with respect to:»
More informationCOMPANY PRESENTATION JULY Bob Bechard Executive Vice-President Corporate Development & Licensing
COMPANY PRESENTATION JULY 2018 Bob Bechard Executive Vice-President Corporate Development & Licensing Forward Looking Statements Some statements in this release may contain forward-looking information.
More informationInvestor Presentation December The vision to see past tomorrow
Investor Presentation December 2011 The vision to see past tomorrow Safe Harbor Statement Certain statements contained herein are forward-looking statements (as such term is defined in the Private Securities
More informationCowen Healthcare Conference
Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT
More informationTitan Pharmaceuticals Overview
Corporate Presentation July 2014 1 Safe Harbor The presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
More informationNovember 2016 NASDAQ: ATRS
November 2016 NASDAQ: ATRS Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of
More informationZacks Small-Cap Research
Zacks Small-Cap Research Sponsored Impartial - Comprehensive August 29, 2018 David Bautz, PhD 312-265-9471 dbautz@zacks.com scr.zacks.com 10 S. Riverside Plaza, Chicago, IL 60606 Opiant Pharmaceuticals,
More informationSucampo Pharmaceuticals, Inc. Jefferies 2015 Healthcare Conference
Sucampo Pharmaceuticals, Inc. Jefferies 2015 Healthcare Conference June 3, 2015 Peter Greenleaf Chief Executive Officer Forward-Looking Statements This presentation contains "forward-looking statements"
More informationAnnual Shareholders Meeting
Annual Shareholders Meeting February 8, 2018 Dow R. Wilson, President and Chief Executive Officer Forward-Looking Statements Except for historical information, this presentation contains forward-looking
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationBDSI Corporate Overview
BDSI Corporate Overview June 2017 1 2017 BioDelivery Sciences International Inc. All Rights Reserved. Jefferies 2017 Healthcare Conference Dr. Mark A. Sirgo President and Chief Executive Officer June 6
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationAVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018
AVENUE THERAPEUTICS, INC. NASDAQ: ATXI JANUARY 2018 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward-looking statements within the meaning
More informationNASDAQ: GWPH March, 2019
NASDAQ: GWPH March, 2019 Grace Living with Dravet syndrome, Being treated with Epidiolex 2019 GW Pharmaceuticals. All rights reserved. Forward-Looking Statements This presentation contains forward-looking
More informationNASDAQ: ZGNX. Company Presentation. October 2017
NASDAQ: ZGNX Company Presentation October 2017 2 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationOWC PHARMACEUTICAL RESEARCH OTCQB:OWCP
OWC PHARMACEUTICAL RESEARCH OTCQB:OWCP Disclaimer This document details business information of OWC Pharmaceuticals Research Corp and/or our wholly-owned Israeli subsidiary, One World Cannabis Ltd. (collectively,
More informationThird Quarter 2015 Earnings Call. November 9, 2015
Third Quarter 2015 Earnings Call November 9, 2015 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements
More informationNASDAQ: Company Update. January 2015
NASDAQ: Company Update January 2015 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements.
More informationHALOZYME REPORTS SECOND QUARTER 2018 RESULTS
Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER
More informationInvestor Presentation March 2015
Investor Presentation March 2015 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking statements within the
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K CURRENT REPORT
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationEgalet Corporate Presentation
Egalet Corporate Presentation Specialty Pharmaceutical Company Focused on Pain 1 NASDAQ: EGLT Forward-Looking Statements Statements included in this presentation that are not historical in nature are "forward-looking
More information37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE
37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as
More informationMerrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007
Merrill Lynch conference Matthew Emmens, CEO Shire plc September 20, 2007 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationCompany Update with a Focus on Pipeline
NASDAQ: Company Update with a Focus on Pipeline December 2014 Forward Looking Statement Zogenix cautions you that statements included in this presentation that are not a description of historical facts
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationAviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about
More informationLEERINK GLOBAL HEALTHCARE CONFERENCE. Marino Garcia EVP, Chief Strategy Officer February 15, 2017
LEERINK GLOBAL HEALTHCARE CONFERENCE Marino Garcia EVP, Chief Strategy Officer February 15, 2017 SAFE HARBOR STATEMENT This presentation and any statements made for and during any presentation or meeting
More informationGW Pharmaceuticals Announces New Physician Reports of Epidiolex(R) Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy
December 7, 2015 GW Pharmaceuticals Announces New Physician Reports of Epidiolex(R) Treatment Effect in Children and Young Adults With Treatment-Resistant Epilepsy As previously announced, seven posters
More informationJefferies Healthcare Conference
Jefferies Healthcare Conference June 7, 2016 NASDAQ: CHMA Forward-Looking Statements These slides contain forward-looking statements and information. The use of words such as may, might, will, should,
More informationGalvus US NDA Approvable - Overview
Galvus US NDA Approvable - Overview Galvus NDA filed with FDA Jan 2006 PDUFA action date extended by 3 months until February 26th 2007 Significant new clinical data added to NDA - Approximately 1000 patient
More informationCorporate Presentation
Carriers Injectable to oral Progressive/Practical Innovation Emisphere Products Corporate Presentation November 2015 Patients OTCBB: EMIS Safe Harbor Statement The statements in this presentation or oral
More information37 th Annual J.P. Morgan Healthcare Conference. January 9, 2019
37 th Annual J.P. Morgan Healthcare Conference January 9, 2019 Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts,
More informationLehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer
Lehman Brothers Eighth Annual Global Healthcare Conference March 30, 2005 Bruce A. Peacock President and Chief Executive Officer 2005 Adolor Corporation. All rights reserved. Safe Harbor Statement This
More informationIpsen Acquisition of Clementia Pharmaceuticals. February 25, 2019
Ipsen Acquisition of Clementia Pharmaceuticals February 25, 2019 Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements,
More information36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018
36th Annual J.P. Morgan Healthcare Conference Kevin Conroy, Chairman and CEO January 9, 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section
More informationDARA Reports Year-End 2012 Financial Results
April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,
More informationAcorda Acquisition of Civitas Therapeutics. September 24, 2014
Acorda Acquisition of Civitas Therapeutics September 24, 2014 Forward Looking Statement This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Jefferies 2016 Healthcare Conference May 2016 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationInnovation In Ophthalmics
Innovation In Ophthalmics Ophthalmic Innovation Summit @ AAO 2018 October 25, 2018 Mark Iwicki Chairman & CEO, Kala Pharmaceuticals Disclaimers and Notices This presentation contains forward-looking statements
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION APRIL 12, 2018 2018 ATOSSA GENETICS, INC. ALL RIGHTS RESERVED. NASDAQ: ATOS WWW.ATOSSAGENETICS.COM 1 Forward-Looking Statements Some of the information presented herein may contain
More informationAvenue Therapeutics, Inc. May 2017
Avenue Therapeutics, Inc. May 2017 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationSPECIALTY MEDICAL CANNABIS COMPANY
SPECIALTY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - August 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationPresentation of ALK London, 24 May 2011 UBS GLOBAL SPECIALTY PHARMACEUTICALS CONFERENCE : LONDON : 24 MAY 2011
Presentation of ALK London, 24 May 2011 1 ALK pharma specialist - treatment, prevention and diagnosis of allergies World leader in allergy immunotherapy ~ 33% global market share Expanding Base Business
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationIdenix Pharmaceuticals Building a Leading Antiviral Franchise. Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston
Idenix Pharmaceuticals Building a Leading Antiviral Franchise Cowen & Company 27 th Annual Healthcare Conference March 13, 2007 Boston Safe Harbor This presentation includes forward-looking statements
More informationAvenue Therapeutics, Inc. September 2016
Avenue Therapeutics, Inc. September 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the
More informationH. LUNDBECK A/S. Teleconference. 10 August PM CET. Financial results Second quarter 2011
H. LUNDBECK A/S Teleconference 10 August 2011-2PM CET Financial results Second quarter 2011 Company disclaimer This presentation contains forward-looking statements that provide our expectations or forecasts
More informationN A S D A Q : E V F M
N A S D A Q : E V F M Jefferies Global Healthcare Conference June 7, 2018 Disclaimer This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform
More informationProprietary Pipeline
Revenue Generating Commercial portfolio with highquality, differentiated products in the Canadian market Proprietary Pipeline Reformulation development pipeline for drugs with a need for improved compliance
More information35 th Annual J.P. Morgan Healthcare Conference
35 th Annual J.P. Morgan Healthcare Conference Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts, regarding management's
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationDiagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015
Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking
More informationCorporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC
Corporate Overview June 2014 Jefferies Healthcare Conference NASDAQ: GLYC Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts
More informationGanaxolone as a Treatment for Drug-Resistant Epilepsy in Children
Ganaxolone as a Treatment for Drug-Resistant Epilepsy in Children ANTIEPILEPTIC DRUG and DEVICE TRIALS XIII May 13-15, 2015 Turnberry Isle Miami Hotel Gail M. Farfel, PhD Chief Development & Regulatory
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationIntercell and Novartis form world leading strategic partnership to drive vaccines innovation
Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell
More informationSPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS
SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator
More informationAradigm Corporation. A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008
Aradigm Corporation A respiratory specialty pharmaceutical company fulfilling unmet needs in pulmonary medicine (ARDM) February 2008 Safe Harbor Statement This presentation contains forward-looking statements
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationA Rare Opportunity in Transplant.
A Rare Opportunity in Transplant. ENV-18-104.0 1 Forward Looking Statements Certain information in this presentation may constitute forward-looking information within the meaning of applicable securities
More informationAct 16 and Medical Cannabis in Pennsylvania
Act 16 and Medical Cannabis in Pennsylvania Charles V. Pollack, Jr., MA, MD, FACEP, FAAEM, FAHA, FESC, FCPP Associate Provost and Professor of Emergency Medicine Director, Institute of Emerging Health
More informationAvenue Therapeutics, Inc. August 2016
Avenue Therapeutics, Inc. August 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe
More informationMedia Kit. September 2017
Media Kit September 2017 About Pear Pear Therapeutics is the leader in FDA-cleared Prescription Digital Therapeutics. The company s approach is to integrate clinically-validated software applications with
More informationSupernus Pharmaceuticals
Supernus Pharmaceuticals Investor Presentation March 2017 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationRevolutionizing how advanced heart disease is treated. Alexei Marko, CEO Chris Clark, CFO November 2014
Revolutionizing how advanced heart disease is treated Alexei Marko, CEO Chris Clark, CFO November 2014 Forward-Looking Statements Statements contained herein that are not based on historical or current
More informationCOMPANY PRESENTATION. Bernard Fortier, CEO
COMPANY PRESENTATION Bernard Fortier, CEO Forward Looking Statements Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationINVESTOR PRESENTATION
INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.
More informationCorporate Presentation
Corporate Presentation March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United States Private Securities
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationCorporate Presentation August 6, 2015
Corporate Presentation August 6, 2015 Creating the Next Generation of CNS Drugs Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events
More informationOWC PHARMACEUTICALS RESEARCH OTCQB:OWCP
OWC PHARMACEUTICALS RESEARCH OTCQB:OWCP Disclaimer This document details business information of OWC Pharmaceuticals Research Corp and/or our wholly-owned Israeli subsidiary, One World Cannabis Ltd. (collectively,
More informationAstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes
AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance Becoming Global Leaders In Diabetes 19th December 2013 Cautionary Statement Regarding Forward-Looking Statements In order,
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION JUNE 26, 2018 2018 ATOSSA GENETICS, INC. ALL RIGHTS RESERVED. NASDAQ: ATOS WWW.ATOSSAGENETICS.COM 1 Forward-Looking Statements Some of the information presented herein may contain
More informationSPECIALTY MEDICAL CANNABIS COMPANY
SPECIALTY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - August 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy DECEMBER 6, 2012 KJETIL HESTDAL, CEO Disclaimer The information included in this Presentation contains certain forward-looking statements that address activities, events
More informationPresentation to 2019 JP Morgan Healthcare Conference
For immediate release 10 January 2019 Presentation to 2019 JP Morgan Healthcare Conference Please find attached CSL Limited s presentation at the 2019 JP Morgan Healthcare Conference. For further information,
More informationInvestment in MGC Pharmaceuticals
Investment in MGC Pharmaceuticals Investor Presentation May 2015 Disclaimer This presentation has been prepared by Erin Resources Limited ( Company ). It does not purport to contain all the information
More informationLauren Silvernail, CFO & VP Corporate Development to present at 2005 Thomas Weisel Partners Healthcare Conference on September 7, 2005 at 3:50 pm EST
Lauren Silvernail, CFO & VP Corporate Development to present at 2005 Thomas Weisel Partners Healthcare Conference on September 7, 2005 at 3:50 pm EST Forward Looking Statements Certain statements contained
More informationDr. Hagit Marchaim, Regulatory Affairs & Drug Development Consulting - HMC
Dr. Hagit Marchaim, Regulatory Affairs & Drug Development Consulting - HMC 1 Disclosures I (Dr. Hagit Marchaim) have no financial relationships to disclose concerning the content of this presentation or
More informationMemory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-
Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -Broadens Roche Nicotinic Alpha-7 Alliance- -Secures Additional $5M Debt Financing to Support Phase 2a Trial-
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Company presentation Per Plotnikof, VP Corporate Communications and IR 1 I ALK at a glance Commercial leader and foremost innovator within respiratory allergies
More informationCorporate overview. September Exploring innovative solutions for acute pain
Corporate overview September 2017 Exploring innovative solutions for acute pain Forward-looking statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationTitan Pharmaceuticals: Highlights
Corporate Presentation January 2013 1 Safe Harbor The presentation may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
More information